who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

How Pfizer (PFE) makes money: Q3 2026 revenue breakdown

US GAAP, Q3 2026 · quarter ended 09/27/2026 · released Nov 3

Net income attributable to Pfizer Inc. common shareholders

$3,242M

down 8.4% y/y

Total revenues

$16,583M

down 0.4% y/y

Next report

~ Feb 2

not announced yet

The quarter in brief

Pfizer's third-quarter 2026 revenues were $16,583 million versus $16,654 million a year earlier (-0.4%), while GAAP net income fell 8% to $3,242 million and diluted EPS declined to $0.56 from $0.62. Pre-tax income from continuing operations edged up to $3,385 million from $3,334 million, but a tax charge of $134 million replaced a $216 million benefit.

Key growth driver: Alliance revenues — the fastest-growing revenue line: $2,851, +24% y/y. · by the Q3 2026 report

How does Pfizer make money?

Pfizer brought in $16.6 billion of revenue in Q3 2026, down 0.4% year over year. The largest source was Product revenues: $13.3 billion, or 80% of the total, followed by Alliance revenues ($2.85B, 17%) and Royalty revenues ($477M, 3%). Net income for the quarter was $3.24 billion, down 8.4% year over year.

Revenue by source, Q3 2026
  • Product revenues$13.3B · 80% · −4.8%
  • Alliance revenues$2.85B · 17% · +24.1%
  • Royalty revenues$477M · 3% · +9.4%

Shares of $16.6B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.

All figures in $M.

Sankey diagram of PFE (Pfizer) earnings report for Q3 2026: revenue, costs and profitProduct revenues$13,255 · −4.8%Alliance revenues$2,851 · +24.1%Royalty revenues$477 · +9.4%Total revenues$16,583 · −0.4%Cost of sales$4,028 · −3.5%Selling,informational andadministrativeexpenses$3,279 · +2.9%Research anddevelopmentexpenses$3,016 · +18.5%Acquiredin-processresearch anddevelopmentexpenses$669 · −51.9%Amortization ofintangible assets$1,128 · −7.8%Restructuringcharges andcertainacquisition-relatedcosts$791 · +177%Other(income)/deductions––net(incl. netinterest expense)$288 · −44.3%Income fromcontinuingoperations beforeprovision/(benefit)for taxes on income$3,385 · +1.5%20.4% marginProvision/(benefit) fortaxes on income$134 · vs −$2164.0% effective rateNet income attributable tononcontrolling interests$10 · +11.1%Net income attributable toPfizer Inc. commonshareholders$3,242 · −8.4%$0.56/sh · 19.6% margin
Sankey diagram of PFE (Pfizer) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Product revenues$13,255 · −4.8%
Alliance revenues$2,851 · +24.1%
Royalty revenues$477 · +9.4%
Total revenues$16,583 · −0.4%
Cost of sales$4,028 · −3.5%
Selling, informational and administrative expenses$3,279 · +2.9%
Research and development expenses$3,016 · +18.5%
Acquired in-process research and development expenses$669 · −51.9%
Amortization of intangible assets$1,128 · −7.8%
Restructuring charges and certain acquisition-related costs$791 · +177%
Other (income)/deductions––net (incl. net interest expense)$288 · −44.3%
Income from continuing operations before provision/(benefit) for taxes on income$3,385 · +1.5% · 20.4% margin
Provision/(benefit) for taxes on income$134 · vs −$216 · 4.0% effective rate
Net income attributable to noncontrolling interests$10 · +11.1%
Net income attributable to Pfizer Inc. common shareholders$3,242 · −8.4% · $0.56/sh · 19.6% margin

Verdict: Pfizer's third-quarter 2026 revenues were $16,583 million versus $16,654 million a year earlier (-0.4%), while GAAP net income fell 8% to $3,242 million and diluted EPS declined to $0.56 from $0.62. Pre-tax income from continuing operations edged up to $3,385 million from $3,334 million, but a tax charge of $134 million replaced a $216 million benefit.

Pfizer raised full-year 2026 revenue guidance to $62.0–64.0 billion from $60.5–62.5 billion and Adjusted diluted EPS guidance to $2.95–3.05 from $2.80–3.00. For the first nine months, revenues rose 2% to $46,067 million while net income fell 40% to $5,681 million. The company paid $7.3 billion of dividends, or $1.29 per share, in the first nine months, completed no share repurchases in 2026 and has $3.3 billion of remaining authorization.

Source and notation

Source: Pfizer earnings release, 8-K EX-99 of 11/03/2026 (SEC EDGAR).

Open as an image: Pfizer (PFE), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Pfizer (PFE) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/pfe. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/pfe"><img src="https://whoreportstoday.com/t/pfe/img/pfizer-pfe-earnings-sankey.png" alt="Pfizer (PFE) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/pfe">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/pfe/img/pfizer-pfe-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/pfe">Pfizer (PFE) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. · Text: Wikipedia, CC BY-SA 4.0, abridged

Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America. Market share (US pharma & biotech): ≈9% by TTM revenue.

Heads-up

Company reports

Q3 2026latest breakdownPfizer's third-quarter 2026 revenues were $16,583 million versus $16,654 million a year earlier (-0.4%), while GAAP net…
Q2 2026A paper loss over a healthy core — the $248M GAAP loss is entirely non-cash impairments ($3.8B for a failed lung-cancer…

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026revenue $62–64B (raised)EPS (non-GAAP) $2.95–3.05revenue $62.6BEPS (GAAP) $1.36revenue −1…+2%

Same quarter a year ago (ended December 31, 2025): revenue $17.56B, EPS (GAAP) −$0.29

How we calculate

Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +1%).

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Nov 3, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

PFE earnings history: past report dates

Nov 3, 2026 Tue8:07 ambefore market openSep 27, 2026$16.6B−0% y/y$0.56−10% y/y
Aug 4, 2026 Tue7:02 ambefore market openJun 28, 2026$15.0B+3% y/y−$0.04
May 5, 2026 Tue7:01 ambefore market openMar 29, 2026$14.5B+5% y/y$0.47−10% y/y
Feb 3, 2026 Tue7:01 ambefore market openDec 31, 2025≈$17.6B−1% y/y≈−$0.29
Nov 4, 2025 Tue7:00 ambefore market openSep 28, 2025$16.7B−6% y/y$0.62−21% y/y
Aug 5, 2025 Tue7:08 ambefore market openJun 29, 2025$14.7B+10% y/y$0.51
Apr 29, 2025 Tue8:02 ambefore market openMar 30, 2025$13.7B−8% y/y$0.52−5% y/y
Feb 4, 2025 Tue8:11 ambefore market openDec 31, 2024≈$17.8B+31% y/y≈$0.07
Oct 29, 2024 Tue8:06 ambefore market openSep 29, 2024$17.7B+31% y/y$0.78
Jul 30, 2024 Tue8:04 ambefore market openJun 30, 2024$13.3B+2% y/y$0.01−98% y/y
May 1, 2024 Wed8:11 ambefore market openMar 31, 2024$14.9B−20% y/y$0.55−43% y/y
Jan 30, 2024 Tue8:04 ambefore market openDec 31, 2023≈$13.5B−46% y/y≈−$0.59
Oct 13, 2023 Fri5:30 pmafter market closeOct 1, 2023$13.5B−40% y/y−$0.42
Aug 1, 2023 Tue8:09 ambefore market openJul 2, 2023$13.0B−53% y/y$0.41−76% y/y
Show all 14 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Pfizer: 15-year financials

202562,5797,7719,075
202463,6278,0319,835
202359,5532,1194,793
2022101,17531,37226,031
202181,28821,97929,869
202041,6519,15912,177
201940,90516,02610,542
201840,82511,15313,843
201752,54621,30814,846
201652,8247,21514,369
201548,8516,96013,291
201449,6059,13515,885
201351,58422,00316,478
201254,65714,57015,419
201161,03510,00918,580

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Pfizer: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
2025208,16086,47664,6381,14242,89836,984
2024213,39688,20363,6051,04350,35842,995
2023226,50189,01471,7572,85343,33347,794
2022197,20595,66135,44441651,25942,138
2021181,47677,20137,8311,94459,69342,671
2020154,22963,2384,5561,78635,06725,920
2019167,59463,14351,3321,12132,80337,304
2018159,42263,40740,7851,13949,92631,858
2017171,79771,30843,1841,34241,14130,427
2016171,61559,54437,1982,59538,94931,115
2015167,38164,72028,8183,64143,80429,399
2014167,56671,30131,5413,34355,59521,587
2013172,10176,30735,5222,18356,24423,366
2012185,79881,26036,18510,08164,83129,186
2011188,00282,19034,9323,18260,81728,909

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow, 2 years

YearCFO · Operating cash flowCAPEX · Capital expenditureFCF · Free cash flowcalculatedFCF margin, %calculatedDividends paidFCF / net income, %calculatedCFI · Investing cash flowCFF · Financing cash flow
20192019-12-31———————−8,485
20182018-12-31———————−20,441
More detailsHide details

$ millions, per fiscal year; ratios in %. “—” — no verified data or calculation not applicable.

* Sources
How we calculate

CFO, CFI and CFF are net operating, investing and financing cash flows. CAPEX is a positive cash outflow for capital expenditure; its scope follows the issuer document line. FCF = CFO − CAPEX; lease repayments are not deducted separately. If no separately sourced numeric CAPEX amount is available, CAPEX and FCF calculations are omitted. FCF margin = FCF / same-year revenue × 100. FCF / net income = FCF / same-year income attributable to shareholders × 100; losses or zero income produce a dash. Revenue and income use this card’s indicators table; missing or mismatched periods produce no ratio. Dividends and common share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows; payments to noncontrolling interests and share-compensation withholding taxes are excluded. Zero requires document evidence. Buybacks appear only if at least one reviewed payment exists in the fifteen-year window. The window is fifteen years; years without a single value are omitted. All listed years stay open; CFI, CFF and buybacks for Russia and Kazakhstan appear under More details.

Snapshot reviewed: . Updated after annual filings and three checks against issuer documents. Unreviewed and interim periods are excluded from the annual series.

More: latest reported period

9 months ended 2026-09-27 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated8,8256,356+2,469
· incl. D&A (non-cash add-back)depreciation & amortization4,8124,905
· incl. stock-based comp (non-cash)share-based compensation883574
Capexpurchases of property & equipment−1,542−1,784+242
Free cash flow ≈operating cash flow − capex7,2834,572+2,711
Investing activities, netcapex, acquisitions, securities8654,795−3,930
Financing activities, netdebt, buybacks, dividends−9,025−10,900+1,875
· incl. dividends paid−7,347−7,326−21
FX effect on cash1636−20
Net change in cash681287+394

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 27, 2026: $89.0B (44% of total assets). Compare with other S&P 500 companies →

Corporate governance

1.5/2mostly good

  • Jul 2016Pfizer agreed to pay $486M to settle a shareholder class action over concealed Celebrex and Bextra risks (court-approved in December 2016); in 2014 it paid $400M in another shareholder suit in New York. sec.gov ↗
  • Feb 202610-K 2025: all common stock is of one class; the legal cases include no shareholder disclosure suits. sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Dec 2025Dividend per share rose from $1.53 (2020) to $1.72 (2025); diluted shares +1.4% over 5 years (XBRL). data.sec.gov ↗

Scoring: 2.0 −0.5 (criterion 9: $486M shareholder settlement over Celebrex/Bextra, approved by the court in Dec 2016) −0.25 (criterion 9: $400M shareholder settlement, 2014 — older than 10 years, half weight) = 1.25 → 1.5

Share classes
Single class of common stock ("all of one class", 10-K 2025 cover).
Dilution
Diluted shares 2020→2025 +1.4%; SBC 1.3% of revenue.
Disclosure
Full reporting, filed on time.
Dividends
Dividend raised every year: $1.53 (2020) → $1.72 (2025).
Lawsuits & regulators
Two shareholder settlements above $50M: $486M (court approval Dec 2016) — full deduction, $400M (2014) — older than 10 years, half weight. No shareholder suits or SEC disclosure cases in the current 10-K.
Related parties
No material related-party transactions disclosed.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Pfizer (PFE) earnings: FAQ

How does Pfizer make money?

Pfizer brought in $16.6 billion of revenue in Q3 2026, down 0.4% year over year. The largest source was Product revenues: $13.3 billion, or 80% of the total, followed by Alliance revenues ($2.85B, 17%) and Royalty revenues ($477M, 3%). Net income for the quarter was $3.24 billion, down 8.4% year over year.

When is PFE's next earnings date?

We have not yet seen an announcement of the date from Pfizer (PFE). Based on last year's report on Feb 3, 2026, the next report is expected around Feb 2, 2027.

What time does PFE report earnings?

Pfizer usually reports before market open: its latest results release was filed with the SEC at 8:07 am ET on Nov 3, 2026.

When did PFE last report earnings?

Pfizer reported Q3 2026 results on Nov 3, 2026.

What has Pfizer guided for FY2026?

Company guidance for FY2026: revenue $62–64B (raised); EPS (non-GAAP) $2.95–3.05. A year ago (FY2025): revenue $62.6B, EPS (GAAP) $1.36. Implied growth: revenue −1…+2%. Source: the company's earnings release (Form 8-K filed Nov 3, 2026).

Where can I find Pfizer's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to PFE's filings; this page breaks the latest report down in a Sankey chart.

What was PFE's net income in Q3 2026?

Pfizer reported net income of $3,242M for Q3 2026 (−8.4% year over year), under US GAAP.

How has Pfizer's revenue changed since 2011?

Per its 10-K filings, revenue was roughly flat: $61,035M in 2011 and $62,579M in 2025. The peak was $101,175M in 2022. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · STE · Q2 FY2027 · SYK · Q3 2026 · TECH · Q4 FY2026 · TMO · Q3 2026 · UHS · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy